Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients

World Journal of Surgery

Volumn 26, Issue 12, 2002, Pages 1405-1411

  Statius Muller, Markwin G ^a   Van Leeuwen, Paul A M ^a   Van Diest, Paul J ^a   Pijpers, Rik ^a   Nijveldt, Robert J ^a   Vuylsteke, Ronald J C L M ^a   Meijer, Sybren ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PROGNOSIS; SENTINEL LYMPH NODE; ADOLESCENT; AGE DISTRIBUTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; INCIDENCE; LYMPH NODE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SEX RATIO; SKIN TUMOR; STATISTICS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SEX DISTRIBUTION; SKIN NEOPLASMS;

EID: 0036886752     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-6197-8     Document Type: Article

References (32)

1. Karakousis CP, Temple DF, Moore R, et al. Prognostic parameters in recurrent malignant melanoma. Cancer 1983;52:575-579
2. Reintgen DS, Vollmer R, Tso CY, et al. Prognosis for recurrent stage I malignant melanoma. Arch. Surg. 1987;122:1338-1342
3. Reintgen DS, Cox C, Slingluff CL Jr, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann. Plast. Surg. 1992;28:45-49
4. Cole DJ, Baron PL. Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection. Semin. Oncol. 1996;23:719-724
5. Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann. Surg. 1982;196:69-75
6. Das Gupta TK. Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study. Ann. Surg. 1977;186:201-209
7. Roses DF, Provet JA, Harris MN, et al. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann. Surg. 1985;201:103-107
8. Koh HK, Sober AJ, Day CL Jr, et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J. Clin. Oncol. 1986;4:1238-1244
9. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial: WHO Melanoma Programme. Lancet 1998;351:793-796
10. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann. Surg. 1981;193:377-388
11. Urist MM, Maddox WA, Kennedy JE, et al. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983;51:2152-2156
12. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J. Clin. Oncol. 1988;6:163-172
13. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-2430
14. Sim FH, Nelson TE, Pritchard DJ. Malignant melanoma: Mayo Clinic experience. Mayo Clin. Proc. 1997;72:565-569
15. Uren RF, Howman-Giles RB, Shaw HM, et al. (1993) Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J. Nucl. Med. 34:1435-1440
16. Drepper H, Kohler CO, Bastian B, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients: results of a multicenter study of 3616 patients. Cancer 1993;72:741-749
17. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann. Surg. 1982;196:677-684
18. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991. J. Am. Coll. Surg. 1995;180:402-409
19. Elder DE, Guerry D IV, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985;56:413-418
20. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 1992;127:392-399
21. Lee YT. Loco-regional recurrent melanoma. I. Natural history. Cancer Treat. Rev. 1980;7:59-72
22. Sugarbaker EV, McBride CM. Melanoma of the trunk: the results of surgical excision and anatomic guidelines for predicting nodal metastasis. Surgery 1976;80:22-30
23. Van der Veen H, Hoekstra OS, Paul MA, et al. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br. J. Surg. 1994;81:1769-1770
24. Pijpers R, Borgstein PJ, Meijer S, et al. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J. Surg. 1997;21:788-792
25. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann. Surg. 1993;218:262-267
26. Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann. Surg. Oncol. 1999;6:315-321
27. Slingluff CL Jr, Stidham KR, Ricci WM, et al. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann. Surg. 1994;219:120-130
28. Van Diest PJ, Peterse HL, Borgstein PJ, et al. Pathological investigation of sentinel lymph nodes. Eur. J. Nucl. Med. 1999;26(Suppl. 4):S43-S49
29. Ward PM, Weiss L. Metachronous seeding of lymph node metastases in rats bearing the MT-100-TC mammary carcinoma: the effect of elective lymph node dissection. Breast Cancer Res. Treat. 1989;14:315-320
30. Gendreau KM, Whalen GF, et al. What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma? J. Surg. Oncol. 1999;70:199-204
31. Eggermont AM. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eur. J. Cancer 1998;34(Suppl. 3):S22-S26
32. Kirkwood JM. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur. J. Cancer 1998;34(Suppl. 3):S12-S17